No Data
128091 GUIYANG XINTIAN PHARMACEUTICAL
Watchlist- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
News
Xintian Pharmaceutical (002873.SZ): Net profit fell 19.36% in the first half of the year to 46,32276 million yuan
GLONGHUI, August 28: Xintian Pharmaceutical (002873.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 526 million yuan, up 0.26% year on year; net profit attributable to shareholders of listed companies was 463276 million yuan, down 19.36% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 42.3624 million yuan, down 23.63% year on year; basic earnings per share were 0.1997 yuan.
Xintian Pharmaceutical (002873.SZ) plans to set up no more than 30 branches to strengthen clinical medical research and independent marketing capabilities
Xintian Pharmaceutical (002873.SZ) announced that the company plans to set up no more than 30 branches, which are mainly responsible for implementation...
Xintian Pharmaceutical (002873.SZ): The fund-raising project is in the commissioning and installation stage of production equipment. It is expected to start production and trial operation in the fourth quarter of this year
On August 11, GLONGHUI | Xintian Pharmaceutical (002873.SZ) said on the event platform that the company's fund-raising projects, the traditional Chinese medicine formula granule construction project and gel and compound production line construction project, completed project construction in June 2023. Currently, it is in the commissioning and installation stage of production equipment, and is expected to enter trial operation in the fourth quarter of this year. The project's acceptance, pre-settlement, production support, equipment commissioning and installation, trial operation, and official commissioning are all progressing in an orderly manner according to the plan.